Cat. No. 2705
Alternative Name: R-75251
Chemical Name: 5-[(3-Chlorophenyl)-1H-imidazol-1-ylmethyl]-1H-benzimidazole hydrochloride
Biological ActivityCytochrome P450 inhibitor. Inhibits several cytochrome P450 enzymes including aromatase (CYP19) and retinoic acid 4-hydroxylase (CYP26). Blocks retinoic acid metabolism (retinoic acid metabolism blocking agent, RAMBA). Displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Van Wauwe et al (1992) Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J.Pharmacol.Exp.Ther. 261 773. PMID: 1374473.
Njar et al (2006) Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg.Med.Chem. 14 4323. PMID: 16530416.
Goss et al (2007) Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. BMC Cancer 7 26. PMID: 17266767.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Liarozole hydrochloride, supplier, Cytochrome, P450, CYP26, inhibitors, blocks, retinoic, acid, metabolism, Blocks, RXR, Retinoid, X, Receptors, CYP, RAR, RAMBA, Retinoic, Acid, R75251
Find multiple products by catalog number
New Products in this Area
Prodrug of the antitumor agent 5F 203Methylprednisolone
Glucocorticoid receptor agonist(Z)-4-Hydroxytamoxifen
Metabolite of tamoxifen (Cat. No. 0999)
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.